Tokuuye K, Akine Y, Sumi M, Kagami Y, Ikeda H, Kaneko A
Department of Radiation Therapy, The National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Radiother Oncol. 1997 Apr;43(1):87-91. doi: 10.1016/s0167-8140(97)01910-5.
Stereotactic radiotherapy used for the treatment of choroidal melanoma made use of a 6-MeV linac with built-in multileaf collimators and a simple plastic head mold. The latter provided excellent head and ocular immobilization. The system resulted in highly localized dose distributions with a maximum 2-mm targeting error during fractionated treatments. Based on these techniques, sixteen patients with choroidal melanoma have so far been treated. Majority of patients received a total dose of 48 Gy in 8 fractions. Fourteen patients who presented with small- to moderate-sized tumors have remained free of relapse or major complications during the follow-up period of 3-42 months. Two patients who presented with an extensive tumor eventually required enucleation after irradiation. Technical precision required for stereotactic radiotherapy and reproducibility for fractionation appear adequate. Encouraging preliminary results justify further studies to evaluate its efficacy as an alternative to other conventional therapeutic approaches.
立体定向放射疗法用于治疗脉络膜黑色素瘤，采用的是一台带有内置多叶准直器的6兆电子伏特直线加速器和一个简单的塑料头部模具。后者能实现出色的头部和眼部固定。该系统在分次治疗期间产生了高度局部化的剂量分布，最大靶向误差为2毫米。基于这些技术，迄今为止已有16例脉络膜黑色素瘤患者接受了治疗。大多数患者接受了8次分割、总剂量为48 Gy的治疗。14例患有小至中等大小肿瘤的患者在3至42个月的随访期内未出现复发或重大并发症。2例患有广泛性肿瘤的患者在放疗后最终需要进行眼球摘除术。立体定向放射疗法所需的技术精度和分次治疗的可重复性似乎是足够的。令人鼓舞的初步结果证明有必要进一步开展研究，以评估其作为其他传统治疗方法替代方案的疗效。
